Inclusion Criteria:

          -  Patients must have a written informed consent.

          -  18 years of age.

          -  Patients must have histologically confirmed recurrent stage III or stage IV melanoma
             (AJCC 7th edition classification).

          -  BRAF V600E and V600K mutated

          -  Cutaneous squamous cell carcinomas (SCC) lesions identified at baseline must be
             excised. Adequate wound healing is required prior to study entry.

          -  Patients must have measurable disease as defined by the Response Evaluation Criteria
             in Solid Tumors v1.1.

          -  Patients must have adequate hematologic, renal, and liver function:

               -  WBC ≥ 3,000/mm3

               -  ANC ≥ 1500

               -  Hb ≥ 9g/dL (women) or ≥ 11g/dL (men) (supportive transfusions will be allowed
                  during induction and maintenance phases to maintain these levels)

               -  Platelets ≥ 100,000/mm3 (supportive transfusions will be allowed during induction
                  and maintenance phases to maintain these levels)

               -  Serum Creatinine ≤ 1.5 x upper limit of normal (ULN)

               -  Serum Bilirubin ≤ 1.5 x ULN

               -  Serum AST/ALT ≤ 2.5 x ULN

          -  EKG documenting normal intervals.

          -  Fully recovered from any effects of major surgery, and be free of significant
             detectable infection.

          -  ECOG performance status of 0 or 1.

          -  Free of active brain metastases by contrast-enhanced CT/MRI scans within 4 weeks prior
             to starting the study drugs.

          -  Female patients of child bearing potential must have a negative pregnancy test (within
             7 days from the time of randomization).

        Exclusion Criteria:

          -  Serious illnesses, such as: cardiovascular disease (uncontrolled congestive heart
             failure, uncontrolled hypertension, cardiac ischemia, myocardial infarction, and
             severe cardiac arrhythmia), bleeding disorders, symptomatic autoimmune diseases,
             severe obstructive or restrictive pulmonary diseases, uncontrolled endocrine disorders
             (hypothyroidism, hyperthyroidism and diabetes mellitus), retinopathy, active systemic
             infections, and inflammatory bowel disorders. This includes known HIV or AIDS-related
             illness, or active HBV and HCV.

          -  Prior therapy (except for adjuvant immunotherapy) with a BRAF and/or MEK and/or ERK
             inhibitors.

          -  Refractory nausea, vomiting, small bowel resection or any other gastrointestinal
             ailment that would preclude study drug absorption.

          -  Cardiac abnormalities

               -  Mean QTc interval ≥ 480 msec at screening.

               -  Recent ACS/AMI - defined as within 24 weeks prior to screening.

               -  Recent PCI/PTCA - defined as within 24 weeks prior to screening.

               -  Recent malignant cardiac arrhythmias - all except sinus arrhythmia within 24
                  weeks prior to screening.

               -  Symptomatic heart failure - NYHA Class ≥ II symptoms.

          -  Active infection or antibiotics within one-week prior to study, including unexplained
             fever Any significant psychiatric disease, medical intervention, or other condition,
             which in the opinion of the principal investigator, could prevent adequate informed
             consent or compromise participation in the clinical trial.

          -  Systemic steroid or other immunosuppressive therapy within 4 weeks of starting the
             study.

          -  Lactating females or pregnant females.